Program
janagliflozin
Also written as “ganagliflozin”, “Janagliflozin plus metformin” and “Janagliflozin 25mg”.
Its studies are mostly in Diabetes Mellitus, Type 2, led by 2 companies.
Drug pageJanagliflozin: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Huadong Medicineits history only | 22 open or running | phase 4since Jul 23, 2025 | Jul 23, 2025 | Dec 31, 2027phase 4 · NCT07244003 |
| Sihuan Pharmaceutical Holdings Group | 20 open or running | phase 3since Jan 17, 2019 | Jan 17, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sihuan Pharmaceutical Holdings Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 17, 2019First study: phase 3 study in Diabetes Mellitus, Type 2First studyNCT03811548 · 442 enrolled · China
- Feb 20, 2019Phase 3 study in Diabetes Mellitus, Type 2NCT03851432 · 390 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 Sihuan Pharmaceutical Holdings Group leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03851432Diabetes Mellitus, Type 2 · China | 3 | UNKNOWN | Apr 30, 2020 | 390 |
| NCT03811548Diabetes Mellitus, Type 2 · China | 3 | UNKNOWN | Jun 24, 2020 | 442 |
How it is read
Names in the registry
- “ganagliflozin”, 2 entries
- “Janagliflozin plus metformin”, 2 entries
- “Janagliflozin 25mg”, 1 entry
- “Janagliflozin 50mg”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.